株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

特発性血小板減少性紫斑病(免疫性血小板減少性紫斑病):パイプライン分析

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, H2 2017

発行 Global Markets Direct 商品コード 237879
出版日 ページ情報 英文 120 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.47円で換算しております。
Back to Top
特発性血小板減少性紫斑病(免疫性血小板減少性紫斑病):パイプライン分析 Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, H2 2017
出版日: 2017年08月22日 ページ情報: 英文 120 Pages
概要

特発性血小板減少性紫斑病(ITP)は、血小板数が減少し、出血しやすくなる疾患です。この疾患の症状には、 切り傷からの出血が止まりにくい、鼻からの突発的な出血、血尿や血便、歯茎からの出血、倦怠感などがあります。ITPの代表的な治療法には、副腎皮質ホルモン(コルチコステロイド)や免疫抑制剤の投与があります。

当レポートでは、世界においてパイプライン中にある特発性血小板減少性紫斑病(免疫性血小板減少性紫斑病)治療薬の概要を提供しており、現在の開発パイプラインの状況や最新動向、後期段階および中止されたプロジェクトの情報、主要企業および彼らが開発中の製品のレビューなどをお届けします。

イントロダクション

  • 調査範囲

特発性血小板減少性紫斑病(免疫性血小板減少性紫斑病)の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

特発性血小板減少性紫斑病(免疫性血小板減少性紫斑病):企業で開発中の治療薬

特発性血小板減少性紫斑病(免疫性血小板減少性紫斑病):大学/機関で研究中の治療薬

特発性血小板減少性紫斑病(免疫性血小板減少性紫斑病):パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

特発性血小板減少性紫斑病(免疫性血小板減少性紫斑病):企業で開発中の製品

特発性血小板減少性紫斑病(免疫性血小板減少性紫斑病):大学/機関で研究中の製品

特発性血小板減少性紫斑病(免疫性血小板減少性紫斑病)の治療薬開発に従事している企業

  • 3SBio Inc.
  • Amgen Inc.
  • Baxalta Incorporated
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • エーザイ
  • Hansa Medical AB
  • Immunomedics, Inc.
  • Intas Pharmaceuticals Ltd.
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Merck & Co., Inc.
  • Momenta Pharmaceuticals, Inc.
  • Novartis AG
  • Pfizer Inc.
  • PhytoHealth Corporation
  • Protalex, Inc.
  • Rigel Pharmaceuticals, Inc.

特発性血小板減少性紫斑病(免疫性血小板減少性紫斑病):治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • 自己免疫疾患・炎症向け阻害剤
  • avatrombopag
  • BI-655064
  • BMS-986004
  • eltrombopag olamine
  • eltrombopag olamine
  • fostamatinib disodium
  • GL-2045
  • GSK-2285921
  • Hetrombopag Olamine
  • MK-8723
  • PBF-1509
  • PHN-013
  • PRTX-100
  • 自己免疫疾患向け免疫グロビンG阻害組み換え酵素
  • romiplostim
  • romiplostim のバイオシミラー
  • SM-101
  • thrombopoietin
  • veltuzumab

特発性血小板減少性紫斑病(免疫性血小板減少性紫斑病):最近のパイプライン動向

特発性血小板減少性紫斑病(免疫性血小板減少性紫斑病):休止中のプロジェクト

特発性血小板減少性紫斑病(免疫性血小板減少性紫斑病):開発が中止された製品

特発性血小板減少性紫斑病(免疫性血小板減少性紫斑病):製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9639IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, H2 2017, provides an overview of the Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) (Hematological Disorders) pipeline landscape.

Idiopathic thrombocytopenic purpura is a bleeding disorder in which the immune system destroys platelets, which play important role in normal blood clotting. Symptoms include blood in urine or stools, fatigue, spontaneous bleeding from nose and superficial bleeding into skin that appears as a rash of pinpoint sized reddish purple spots, usually on lower legs.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 5, 8, 3, 2 and 7 respectively.

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) (Hematological Disorders).
  • The pipeline guide reviews pipeline therapeutics for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) (Hematological Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) (Hematological Disorders)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) (Hematological Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Overview
    • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Companies Involved in Therapeutics Development
    • 3SBio Inc
    • Amgen Inc
    • arGEN-X BV
    • Biogen Inc
    • Boehringer Ingelheim GmbH
    • Bristol-Myers Squibb Company
    • CSL Ltd
    • Dova Pharmaceuticals Inc
    • Enzene Biosciences Ltd
    • Genosco Inc
    • GlaxoSmithKline Plc
    • Hansa Medical AB
    • Immunomedics Inc
    • Intas Pharmaceuticals Ltd
    • Jiangsu Hengrui Medicine Co Ltd
    • Momenta Pharmaceuticals Inc
    • Novartis AG
    • Pfizer Inc
    • Pharmagenesis Inc
    • Protalex Inc
    • Rigel Pharmaceuticals Inc
    • UCB SA
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Drug Profiles
    • avatrombopag - Drug Profile
    • belimumab - Drug Profile
    • BI-655064 - Drug Profile
    • efgartigimod alfa - Drug Profile
    • eltrombopag olamine - Drug Profile
    • eltrombopag olamine - Drug Profile
    • fostamatinib disodium - Drug Profile
    • GL-2045 - Drug Profile
    • Hetrombopag Olamine - Drug Profile
    • KLM-465 - Drug Profile
    • letolizumab - Drug Profile
    • M-230 - Drug Profile
    • M-254 - Drug Profile
    • M-281 - Drug Profile
    • PBF-1650 - Drug Profile
    • PHN-013 - Drug Profile
    • PRTX-100 - Drug Profile
    • Recombinant Enzyme to Inhibit Immunoglobulin G for Autoimmune Diseases - Drug Profile
    • rituximab - Drug Profile
    • romiplostim - Drug Profile
    • romiplostim biosimilar - Drug Profile
    • romiplostim biosimilar - Drug Profile
    • rozanolixizumab - Drug Profile
    • SKIO-703 - Drug Profile
    • thrombopoietin - Drug Profile
    • veltuzumab - Drug Profile
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Dormant Projects
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Discontinued Products
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by 3SBio Inc, H2 2017
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Amgen Inc, H2 2017
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by arGEN-X BV, H2 2017
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Biogen Inc, H2 2017
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Boehringer Ingelheim GmbH, H2 2017
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Bristol-Myers Squibb Company, H2 2017
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by CSL Ltd, H2 2017
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Dova Pharmaceuticals Inc, H2 2017
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Enzene Biosciences Ltd, H2 2017
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Genosco Inc, H2 2017
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by GlaxoSmithKline Plc, H2 2017
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Hansa Medical AB, H2 2017
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Immunomedics Inc, H2 2017
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Intas Pharmaceuticals Ltd, H2 2017
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2017
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Momenta Pharmaceuticals Inc, H2 2017
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Novartis AG, H2 2017
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Pfizer Inc, H2 2017
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Pharmagenesis Inc, H2 2017
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Protalex Inc, H2 2017
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Rigel Pharmaceuticals Inc, H2 2017
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by UCB SA, H2 2017
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Dormant Projects, H2 2017
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top